Have a personal or library account? Click to login
Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer Cover

Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

Radiology and Oncology
Volume 56 (2022): Issue 2 (June 2022)
By:
Open Access
|Apr 2022

Additional Files

Supplementary Material 1

DOI: https://doi.org/10.2478/raon-2022-0012 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 185 - 197
Submitted on: Sep 26, 2021
Accepted on: Jan 28, 2022
Published on: Apr 7, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
vactosertib,
transforming growth factor-β (TGF-β),
radiotherapy,
epithelial-to-mesenchymal transition,
cancer stem cell,
breast cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Jiwon Choi, Jiyoung Park, Ilyoung Cho, Yhunyhong Sheen, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 56 (2022): Issue 2 (June 2022)Next article